Abstract:Sorafenib is one of the clinically used anticancer agents that inhibits several kinases. In this study, novel indole-based rigid analogues of sorafenib were designed and synthesized in order to enhance kinase selectivity and hence minimize the side effects associated with its use. The target compounds possess different linkers; urea, amide, sulfonamide, or thiourea, in addition to different terminal aryl moieties attached to the linker in order to investigate their impact on biological activity. They were tested against Hep3B, Huh7, and Hep-G2 hepatocellular carcinoma (HCC) cell lines to study their potency. Among all the tested target derivatives, compound 1h exerted superior antiproliferative potency against all the three tested HCC cell lines compared to sorafenib. Based on these preliminary results, compound 1h was selected for further biological and in silico investigations. Up to 30 μM, compound 1h did not inhibit 50% of the proliferation of WI-38 normal cells, which indicated promising selectivity against HCC cells than normal cells. In addition, compound 1h exerted superior kinase selectivity than sorafenib. It is selective for VEGFR2 and VEGFR3 angiogenesis-related kinases, while sorafenib is a multikinase inhibitor. Superior kinase selectivity of compound 1h to sorafenib can be attributed to its conformationally-restricted indole nucleus and the bulky N-methylpiperazinyl moiety. Western blotting was carried out and confirmed the ability of compound 1h to inhibit VEGFR2 kinase inside Hep-G2 HCC cells in a dose-dependent pattern. Compound 1h induces apoptosis and necrosis in Hep-G2 cell line, as shown by caspase-3/7 and lactate dehydrogenase (LDH) release assays, respectively. Moreover, compound 1h is rather safe against hERG. Thus, we could achieve a more selective kinase inhibitor than sorafenib with retained or even better antiproliferative potency against HCC cell lines. Furthermore, molecular docking and dynamic simulation studies were carried out to investigate its binding mode with VEGFR2 kinase. The molecule has a unique orientation upon binding with the kinase.

Synthesis of Deuterium-Enriched Sorafenib Derivatives and Evaluation of Their Biological Activities

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

Synthesis and Biological Evaluation of Sorafenib Thiourea Derivatives

Design, synthesis, and bioactivity evaluation of antitumor sorafenib analogues.

, and bioactivity evaluation of antitumor sorafenib analogues

Design and Synthesis of Hydrazine and Oxadiazole-containing Derivatives of Sorafenib As Antitumor Agents

Design, Synthesis and Biological Activities of Sorafenib Derivatives As Antitumor Agents

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

Evolution in Medicinal Chemistry of Sorafenib Derivatives for Hepatocellular Carcinoma.

Thiourea and thioether derivatives of sorafenib: synthesis, crystal structure, and antiproliferative activity

Design, synthesis and biological evaluation of thiourea and nicotinamide-containing sorafenib analogs as antitumor agents

Preparation and Evaluation of Folate-Decorated Human Serum Albumin Nanoparticles for the Targeted Delivery of Sorafenib to Enhance Antihepatocarcinoma Efficacy

Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study

Design, Synthesis and Antiproliferative Activities of Diaryl Thiourea Derivatives as Anticancer Agents

A New Sorafenib Isoster and its Rearrangement Product: Synthesis, Characterization, and in Vitro Cytotoxicity and Enzyme Inhibition Studies

Preparation, Pharmacokinetics, Tissue Distribution and Antitumor Effect of Sorafenib-Incorporating Nanoparticles in Vivo.

Pharmacokinetics and apparent Michaelis constant for metabolite conversion of sorafenib in healthy and hepatocellular carcinoma-bearing rats

Synthesis of deuterium-enriched and fluorine-substituted plinabulin derivatives and evaluation of their antitumor activities

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

In Vivo Biodistribution, Biocompatibility, and Efficacy of Sorafenib-Loaded Lipid-Based Nanosuspensions Evaluated Experimentally in Cancer

Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells